In accordance with previous small cohort studies, the highest occurrence and expression levels were observed for SSX1 and SSX2, with 89% of primary melanomas and 88% of metastases having expression of either SSX1, SSX2 or both (Figure 1B). The gene discussed is SSX2; the disease is melanoma.